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Gofer and  Amos  reported presence of  the  "X"  antigen  in  certain mouse 
leukemias (1). On further study, three distinct X  antigens, which appeared to 
be present specifically in C57BL leukemia.s,  were found (2). Slettenmark and 
Klein showed that  mice  can  develop specific cytolytic isoantibodies against 
isologous Gross virus leukemia cells; such isoantibodies could not be obtained 
by immunization with normal lymph node cells (3). None of these workers re- 
lated the specificities shown to specificity against thymus. 
Old,  Boyse, and  Stockert reported  that  isoantisera prepared in  C57BL/6 
mice against radiation-induced leukemias of strain A origin were cytolytic for 
certain leukemias of strain A and strain C57BL/6 origin. The cytolytic activity 
was absorbed by thymus of strain A or C58 origin. These data indicated pres- 
ence of a  common antigen, the LT antigen, in the tissues mentioned. The LT 
antigen was not found in any normal tissue other than thymus in A mice, nor 
in any normal tissue in C57BL/6 mice. Nor was it present in thymus or leu- 
kemias of AKR and certain other strains of mice (4). 
Following  a  single  observation  of  substantial  cytolysis of  mouse thymic 
lymphocytes by Gofer and Boyse (5), we investigated a  system for immune 
cytolysis of mouse thymic lymphocytes (6-8). In this system, an isoantiserum 
prepared in C3HeB/Fe mice against AKR thymic lymphocytes showed strong 
cytolytic potencies against the latter cells,  despite compatibility in H-2 allele 
(7).  It was  concluded that  one  or more strong  antigens  are present  on  the 
surface of AKR thymic lymphocytes (9). The present report extends our pre- 
vious findings (7, 9). A preliminary report has been made (10). 
Materials and Methods 
Mouse Strains and Isoantisera.--Unless stated otherwise, all work was done with inbred 
mice of either sex, 5 to 12 weeks old, obtained from the Jackson Laboratory. Tissues  from AKR 
mice were injected into C3HeB/Fe mice that possess the same allele H-2  k or  H-2  k', or into 
C57BL/6 mice that possess the allele  H-2  b. A group of 9 to 27 mice  was used for preparation of 
each isoantiserum. 
* This investigation was supported by grants CY-4469 and CA 04469-06 AI from The 
National Cancer Institute, National Institutes of Health, Public Health Service. 
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In general, six injections spaced at weekly intervals were given. The following quantities of 
AKR tissues were injected intraperitoneally each time: for thymocytes and marrow, 10 million 
viable cells; for red blood cells, 0.4 ml of a 30 per cent suspension;  for spleen, lymph nodes, and 
liver, 0.4 mi of a 30 per cent homogenate. For the solid tumors BW5147,  $775, and T283, 0.3 
ml of a tissue mince was injected subcutaneously. 
IA946 leukemia will take when injected intraperitonealJy at high doses into C3HeB/Fe mice 
(9). Therefore  100,000  viable L4946  cells were injected intraperitoneally,  followed 3  weeks 
later by 10 million cells aged for 1 week at 3°C, and 2 weeks later by 10 million viable cells. 
C57BL/6 mice, which reject IA946 leukemia (9), received 6 weekly intraperitoneal injections 
of 10 million viable cells. For red cells,  thymocytes, spleen,  and tumors BW5147,  $775, and 
T283,  an additional subcutaneous injection of tissue incorporated in Freund-McDermott ad- 
juvant (11, 12) was given initially. Blood was obtained by cardiac puncture 10 days after the 
TABLE I 
Data on AKR Leukemias  Used in This Study 
Designation 
L4946 
BW5147 
$775 
RA1 
RA2 
RA3 
tA4 
RA5 
Worker or 
laboratory 
L.W.L. 
Jackson 
G.D.S. 
Tufts 
Tufts 
Tufts 
Tufts 
Tufts 
Date offirst 
transplant 
1951 
1954 
Feb. 15, 1952 
Sept. 20, 1963 
Oct. 9, 1963 
Nov. 5, 1963 
Nov. 12, 1963 
Dec. 9, 1963 
AKR tissue 
used for 
transplant 
Spleen and 
nodes 
Spleen 
Marrow 
Thymus 
Marrow 
Thymus 
Transplant 
generation 
March 1, 
1964 
+200 
+200 
+200 
10 
Lost 
11 
6 
6 
Approxl- 
mate mean 
time to 
death* 
days 
11 
12 
14 
18 
14 
11 
18 
25 
Tissue of origin 
determined in 
this study 
Non-thymic 
Thymic 
Thymic 
Non-thymic 
Thymic 
Thymic 
Non-thymic 
Thymic 
* Peritoneal  cavity of tumor-bearing  mouse washed  out with 2  ml sterile saline.  Then 
0.2 ml aliquots of fluid injected intraperitoneally into AKR mice. 
last injection. For each group of mice, the sera were pooled, inactivated for 30 minutes at 56°C, 
and stored at --20°C without addition of preservative. 
Tumors.--Eight  leukemias  (Table I) and  osteogenic sarcoma T283 were used;  all  these 
tumors originated spontaneously in AKR mice. The leukemias BW5147  and $775 (the latter 
provided through the courtesy of Dr. G. D. Snell) were converted to ascites form in our labora- 
tory. Sarcoma T283 resisted this conversion. 
The five newly derived ascjtes tumors (Table I) were obtained by the transplantation  of 
ceils from spontaneously leukemic AKR mice 7 to 12 months of age. Sterile isotonic saline that 
contained 100 I.V. penicillin G and 100 #g streptomycin per ml was used to prepare minces or 
single cell suspensions  (see below)  of leukemic tissues for intraperitoneal injection into AKR 
mice. Tumor  takes,  certified by biological and  histological evidence, were  obtained  in all 
transplants  from leukemic mice. 
Cell Suspensions.--For  use in immunizations and cytolysis, suspensions  of red blood cells 
(13),  thymic lymphocytes (8), and  tumor cells (12) of mice were prepared as previously de- 
scribed.  Cells were kept at 0-5°C unless otherwise specified.  In cytolysis and  in absorption 
studies, cells were used within 2 hours after preparation. ARNOLD  E.  RE1T  AND  JOAN  M.  V.  ALLEN  415 
Spleens were pressed through a 60-mesh stainless steel screen into modified Locke's solution 
(12), and a single cell suspension was prepared by the method of M6ller (14). Intraperitoneal 
lymphocytes were washed from the peritoneal cavity with the same buffer, centrifuged at 5°C 
for 10 minutes at 90 g, and resuspended in fresh buffer. Lymph nodes were suspended in buffer 
and teased with needles; the lymphocytes that resulted were filtered through an 80-mesh 
stainless steel screen. 
Bone marrow cells were expelled from femurs into modified Locke's solution. Cell dumps 
were disrupted by suction into a hypodermic syringe. The suspension was centrifuged at 5°C 
for 10 minutes at 135 g, redispersed in fresh buffer, and filtered through an 80-mesh stainless 
steel screen. 
Compl~n~nt.--Fresh guinea pig serum was absorbed twice for 30 minutes at 3°C with 1/20 
volume of packed ~  crythrocytes. The serum was stored at --40°C in sealed 1.5 nd pyrex 
ampoules. Fresh hamster serum was absorbed twice with 1/20 volume of ~  erythrocytes 
and three times with 1/10 volume of packed AKR liver homogenate and stored frozen in like 
manner  (8). 
Cytolysis Assay System.--The  cytolytic potency of isoantisera was determined in the small- 
scale assay system previously described in detail (12). The only change was use Of 100,000 cells 
per assay tube; also, an incubation period of 1 hour rather th~n 1~ hOurS at 37°C was used for 
all cells other than the three long-transplanted leukemias. For cytolysis of  thymocytes,  ab- 
sorbed hamster serum rather than absorbed guinea pig serum was employed as complement 
(8). Cytolytic titers were based on the stained cell count rather than on the deformed cell count, 
since thereby a closer proportionality between cytolytic titer and cell concentration in the as- 
say system was obtained (12). 
The results for each isoantiserum were plotted to give the cytolytic titer, defined as the final 
concentration of antiserum ( per cent) that caused 50 per cent staining of intact cells present in 
the control tube. Factors were determined (see Results) to convert titers obtained in the small- 
scale assay system to the basis of the regular assay system, in which the cell concentration was 
5 million cells/ml (8, 12). The potency of each isoantiserum was expressed at 100 divided by 
the cytolytic titer obtained in the regular assay system (13). 
No isoantiserum was tested at a final concentration above 17 per cent. A titer obtained at 
this level in the small-scale assay system corresponded to a titer of 3.6 X  17 or 61 per cent in 
the regular assay system, since the latter was less sensitive by a factor of 3.6 (mean value ob- 
tained for different cell types, see Results). Thus, depending on the cell types assayed,  the 
minimum cytolytic potency that could be quantified was approximately 100/61 or 1.6. 
A potency of 1000 corresponded to a final isoantiserum concentration of 0.1 per cent in the 
regular assay system, or 0.03 per cent in the small-scale assay system (Fig. 1, top). Titers were 
generally sharp and had standard deviations of 20 to 30 per cent when determined in different 
experiments; deviations were lower when the relative potencies of several antisera were deter- 
mined in a single experiment (8, 11, 12). Potencies below approximately 7 were subject to error 
because of the occasional presence of prozones (Fig.  1, bottom), and have therefore far less 
quantitative validity. 
If an isoantiserum caused between 40 and 50 per cent cell staining and no prozone was evi- 
dent, the cytolytic curve (Fig.  1,  top) was extrapolated to 50 per cent and a  titer was  re- 
corded. If staining was between 10 and 40 per cent orif a prozone was evident, the record shows 
the highest percentage of stained cells above control (per cent a.c.) obtained at any dilution 
that was tested. Stained cell counts under 10 per cent were not considered significant (com- 
pare with reference 15), and the potency of the isoantisernm is stated to lie below the minimum 
that could be quantified (<2). 
When two different types of cells could be distinguished in the cytolytic system (Fig. 2, top), 
the titer was read as the final concentration of antiserum that caused 50 per cent staining of the 
intact cells of a specified type. _1 
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Fio. 1. Top: Example of a potent isoantiserum.  Cytolytic titration  of thymocytes from 
adult (O--Q) and newborn (O--O) ~  mice by C3HeB/Fe isoantiserum to AKR thymo- 
cytes. Cytolyfie titers were read at the final concentrations of isoantiserum corresponding to 
the arrows. 
Bo#om: Example of a strong prozone. Cytolytic titration of BW5147 leukemia by C3HeB/ 
Fe isoantiserum to BW5147 leukemia. 
I00 
80 
6O 
40 
2_0  ° 
w  002  005 0:1  2 
o 
o  IO0  W 
Z 
l-- 
m  60 
40 
20 
0  0.1 
05  2  4 
0"2  05  I  2  5  I0  20 
FINAL  CONCENTRATION  OF  ISOANTISERUM,  % 
FIG. 2. Top:  Differentiation between leukemic and normal lymphocytes in peritoneal cells 
from an AKR mouse that carried the 4th transplant  generation of leukemia RA2. Cytolytic 
titration of peritoneal cells by C3HeB/Fe isoantiserum to AKR spleen,  toxic only to the leu- 
kemic cells (O--O), and by C57BL/6 isoantiserum to IA946 leukemia (O--O), toxic both 
to the leukemic and to the normal peritoneal cells. 
Bottom:  Cytolytic titration of supematants from an absorption experiment. Aliquots of 0.1 
ml C3HeB/Fe isoantiserum to AKR thymocytes (in i  to 10 dilution) were absorbed with the 
stated numbers (millions)  of AKR thymocytes. The supernatants were diluted 1 to 4 and ti- 
trated as shown against AKR thymocytes. 
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Absorptions.--An adaptation of the method employed by M6Uer  (16) and by Amos and 
coworkers (17) was used. Aliquots of suspensions that contained known numbers of single cells 
were centrifuged at 5°C for 10 minutes at 220 g and the supematant was removed. Tissues that 
do not easily yield single cell suspensions  were homogenized  in modified Locke's solution to 10 
per cent on a wet weight basis. After centrifugation at 5°C for 10 minutes at 2000 g, the super- 
natant was removed and the residue resnspended (or,  ff necessary, rehomogenized) in the 
original volume of buffer. Then suitable aliquots were recentrifuged to give packed residues 
derived from a known wet weight of intact tissue. These residues were stirred to a slurry-like 
consistency. 
Absorptions  were carried out at room temperature. One volume of isoantiserum dilution was 
added to the requisite quantities of single cells or tissue residues, and mixed every 5 minutes 
for 30 minutes. Then the tubes were placed in ice water, 3 volumes of cold buffer added, and 
the contents mixed. Tubes were centrifuged at 5°C for i0 minutes at 700 g or 2400 g, for con- 
tents of single ceils or tissue residue, respectively. The supematants were decanted and stored 
at --20°C. They were subsequently titered by cytolysis against the appropriate cell type. 
RESULTS 
Assay Systems.-- 
Cytolytic assays: Perhaps  the  most  important  criterion  for  validity of  a 
cytolytic assay is the dependence of cytolytic titer on cell concentration. This 
criterion was satisfied over specified ranges of cell concentration in the assays 
previously investigated (8, 11, 12, 18) and in those assays that were tested in 
this study (Table II). Ideally, the dependence should be direct proportionality, 
but in practice this has been attained only in one instance, in work with heter- 
ologous antiserum (8). 
Factors  were  determined  to  convert  fiters  obtained  with  the  small-scale 
assay system to titers based on the regular assay system (12).  For each cell 
type, two isoantisera were fitered simultaneously in both assay systems and 
the same experiment was repeated on another day. The small-scale assay system 
TABLE II 
Relationship  between Cell Concentration and Cytolytio Titer.  Cytolysis of Various  AKR  Cell 
Types by C57BL/6 Isoantisera* 
Relative cytolytic  titer at stated cell concentrations,  compared to the cytolytic 
titer (100) at a final cell concentration  of 5 million  cells/ml 
Final cell concentration 
in assay system, 
millions 
$775 leukemia 
10 
5 
2.5 
1.25 
Thymocytes: 
data from 
reference  8 
174 
100 
67 
47 
Splenic 
lymphocytes 
141 
100 
60 
35 
Lymph  node 
ymphocytes 
147 
100 
40 
26 
148 
100 
72 
56 
* All results are the mean for two experiments, except for BW5147 leukemia. 
BW5147 
leukemia 
155 
100 
65 
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was more sensitive than the regular assay system by a factor of 3.7,  2.7,  2.3, 
2.7, 4.0, 5.3, 3.4, 3.7, 4.2,  and 3.7, for thymic, lymph node, splenic, intraperi- 
toneal, L4946, BW5147, $775, RA1, RA2, and RA3 cells, respectively. 
No isoantiserum tested in this study cytolyzed more than 20 per  cent of 
marrow  cells.  Even use  of a  rabbit  antiserum against mouse marrow  cells, 
prepared in the same manner as the antiserum against thymocytes (8), did not 
result in a  satisfactory assay system: cytolytic titers were shallow, and the 
dependence of cytolytic titer on cell concentration was low, even though com- 
plementation was adequate. These data suggest that the surface properties of 
marrow cells, rather than the inadequacy of the assay system, are responsible 
for the present results with marrow cells. 
Quantitative absorption experiments: A new quantitative method was used to 
calculate absorption of isoantisera by viable cells and packed tissue residues. 
The method is illustrated by Table III and Fig. 2, bottom, and Fig. 3. The final 
result for each tissue is a simple and direct estimate of absorptive capacity. 
An isoantiserum was absorbed with a known number of intact cells or with a 
packed residue derived from a  homogenate of a  known wet weight of tissue 
(Table  III).  Control absorptions were done with tissues  obtained from the 
strain of mouse (C3Heb/Fe) in which the isoantiserum had been prepared. The 
supernatant that remained after absorption was titered against AKR thymo- 
cytes (Fig.  2, bottom, and Table III). The potency of the supernatant was 
calculated as a percentage of the potency before absorption. When this potency 
was plotted on logarithmic probability paper against the number of thymocytes 
used for absorption, a straight line was obtained (Fig. 3). This line served as a 
calibration curve to express the reduction in potency obtained by absorption 
with any tissue (Table III) in terms of the equivalent number of AKR thymo- 
cytes required to produce the same reduction in potency. A slight correction 
was applied for absorption by control tissues. The absorptive capacity of intact 
single cells (or of tissue residues) was calculated as a percentage of the absorp- 
tive capacity of the same number of AKR thymocytes (or of thymic residue 
derived from the same wet weight of tissue). Thus in every experiment, AKR 
thymocytes (or AKR thymic residue) were included to provide a  standard of 
absorption; in addition, a complete calibration curve was occasionally run. 
Thymic residues could not be redispersed adequately by manual mixing with 
isoantiserum during the absorption period. When absorptions were performed 
with occasional mechanical mixing in a small pyrex homogenizer (Macalaster- 
Bicknell Company, Cambridge, Massachusetts, No. 2976), 38 per cent greater 
absorption of isoantiserum was obtained. Under the latter conditions, residue 
from a homogenate of 1 mg wet weight of thymus gland absorbed as much iso- 
antiserum as 2.25 million fresh thymocytes (mean value of four determinations). 
Positive results in absorption experiments were reproducible if the absorptive 
capacity exceeded 1.5 per cent. The sensitivity of the method varied with the TABLE HI 
Results and Calculations  for Two Typical Absorption Experiments 
0.1 ml of 1 to 10 dilution of C3HeB/Fe 
isoantiserum against AKR thymocytes, 
absorbed with: 
I  Quantity,  millions  Strain  Tissue  of cells 
Unabsorbed antiserum 
AKR  Thymocytes 
C3HeB/Fe  Thymocytes 
AKR  Splenic lymphs 
C3HeB/Fe  Splenic lymphs 
C•fitolytic  ter of 
superna- 
tant  a~t 
thy- 
mocytes 
Equiva- 
lent No. ot 
AKR 
I  thymo- 
Potency [cytes, read 
of  super- from log- 
natant*  l?robabil- 
its. plo)t t 
Correc- 
tion for 
absorp- 
tion by 
control 
tlssue~, 
~illlons 
of cells 
Corrected 
equivalent 
No. of 
AKR  thy. 
mocytes, 
millions 
of cells 
Absorp- 
tive 
i eapacity 
relative 
to AKR 
thymo- 
cytes§ 
per cen~  >er cent  per cent 
Absorptions with intozt sin le ceils 
0.1 
0.86 
2.6 
1.00 
2.66 
0.86 
2.5 
1.80 
0.30  100 
3  0.92  32.6 
30  0.40  75.0 
41  0.97  30.9 
41  0.38  78.9 
100 
5.3 
Absorptions with residues  from tissue twmogenates 
mg~ 
Unabsorbed antiserum 
AKR  Thymus 
C3HeB/Fe  Thymus 
AKR  Brain 
C3HeB/Fe  Brain 
2 
20 
1.6 
16 
0.21 
3.4 
0.29 
1.91 
0.31 
100 
6.2 
72.4 
11.0 
67.8 
6.4 
1.03 
4.9 
1.17 
0.1 
0.1 
6.3 
4.8 
100 
95 
titer of unabsorbed  antiserum 
* The potency of the supernatant is 100 X  titer of supemataut from absorption =  per cent. 
For  instance,  after absorption  with  3  million  AKR  thymocytes,  the  potency  is 
0.30 
100 X  ~  =  32.6 per cent. 
No.  of cells (or residue weight) used in experimental absorption 
The correction is  No. of cells (or residue weight) used in control absorption  X 
equivalent No. of thymocytes for control absorption. 
For instance, for absorption by 3 million AKR thymocytes, the correction is ~0 X  1.00 
ffi  0.1. 
§ Absorptive capacity is 
equivalent No. of AKR thymocytes per million experimental cells 
100  X  ffi per cent. 
equivalent No. of AKR thymocytes per million thymocytes used 
For  instance,  for  absorption  by  AKR  splenic  lymphocytes,  absorptive  capacity 
1.80/41 
is 100  X  --  -- 5.3 per cent.  2.5/3 
For tissue residues, absorptive capacity is 
equivalent No. of AKR thymocytes per mg experimental residue 
100 X  -~ per cent. 
equivalent No. of AKR thymocytes per mg thymic residue 
4.8/1.6 
For instance, for absorption by AKR brain, absorptive capacity is 100 X  5.3/~  95 
per cent. 
H  Residue from homogenates, derived from stated wet weight of tissue. 
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quantity of tissue used for absorption. It was optimal when the largest quantity 
was employed that would still leave sufficient  cytolytic potency in the super- 
natant to permit accurate determination of that potency. 
Serological Data.-- 
Cytolysis  of normal AKR lympkocytes  by C3HeB/Fe isoantisera:  C3HeB/Fe 
mice possess the same H-2 allele  as AKR mice but presumably differ in other 
histocompatibility factors  (17).  Surprisingly,  all  C3HeB/Fe  isoantisera cyto- 
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FIG. 3.  Calibration curve for an absorption experiment, plotted on logarithmic probability 
paper. Percentage of original cytolyfic potency that remains in the supernatant (abscissa)  fol- 
lowing absorption with a stated number of thymocytes (ordinate).  Data taken from Fig. 2, 
bottom (@--0), and from an identical repeat experiment (O--O). 
lyzed AKR thymocytes, while none cytolyzed other types of lymphocytes or 
marrow cells of normal AKR mice (Table IV). Very different  results were ob- 
tained with isoantisera prepared in a strain that differed in H-2 allele (Table V). 
Contrary to expectation, the C3HeB/Fe  isoanfiserum against AKR spleen 
was more potent in  cytolysis  of AKR  thymocytes than  the  C3HeB/Fe  iso- 
antisenan  against  AKR  thymocytes  (Table  IV).  Isoanfisera  against  AKR 
lymph node cells, washed blood cells, and marrow were approximately one-fifth, 
one-fifteenth,  and  one-fifteenth  as  potent,  respectively  (Table  IV).  These 
results are partially explained by absorption experiments  (Table  VI).  Thus, 
splenic  and  lymph  node  lymphocytes  did  absorb  C3HeB/Fe  isoantiserum 
against AKR thymocytes, although not avidly. In general, there was some cor- 
relation between the potency of isoantisera prepared against normal tissues and TABLE  IV 
Cytolysis of Normal AKR Cells by Isoantgsera Prepared in C3HeB/Fe Mice (Same H-2 Allele) 
Against AKR Cells* 
CtHeB/Fe isoantisera against 
the following AKR cell types: 
Washed blood cells  ........... 
Thymocytes ................. 
Lymph nodes  ................ 
Spleen ...................... 
Marrow .................... 
Liver ....................... 
L4946 leukemia .............. 
BW5147 leukemia ........... 
$775 leukemia ............... 
T283 sarcoma ............... 
Potency~ of C3HeB/Fe isoanfisers for cytolysls of the following 
normal AKR cell types: 
Thymocytes 
36 
450 
101 
524 
33 
9 
340 
261 
30 
15 
Lymph 
node cells 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
Spleen 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
Intraperi- 
toneal 
lymphocytes 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
Marrow 
<2 
<2 
n.t.§ 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
* Each value represents the mean result  of two  determinations performed  on  different 
days. 
:~  Potency is expressed as 100/cytolytic titer. 
§  n.t.,  not tested. 
TABLE  V 
Cytolysls of Normal AKR Cells by Isoa~isera Prepared in C57BL/6 Mice 
(Differ in H-2 Allele) against AKR Cells* 
C57BL/6 isoanfisera against 
the following AKR cell types: 
Washed blood cells  ......... 
Thymocytes  ............... 
Lymph nodes ............. 
Spleen .................... 
Marrow .................. 
Liver ..................... 
L4946 leukemia  ........... 
BW5147 leukemia .......... 
$775 leukemia .............. 
T283 sarcoma ............ 
Potency of C57BL/6 isoantisera  for cytolysis of the following normal 
AKR cell types: 
~ymo- 
cytes 
290 
450 
<2 
1.6 
<2 
<2 
4 
5.9 
8.6 
<2 
Lymph 
node cells 
36 
61 
30 
660 
1.8 
10.9 
53 
47 
27 
3.0 
Spleen  ] 
62 
82 
77 
'10 
9§ 
16.3§ 
Intraperitoneal 
lymphocytes 
23 
9 
(20  % a.c.)~ 
137 
(17 %  a.c.) 
(2S  % a.c.) 
.12  32 
66  21 
34  I  8.6 
4.4§  <2 
Marrow 
2 
2 
2 
(21% a.c.) 
2 
2 
(21% a.c.) 
(12 % a.c.) 
<2 
<2 
* Each value represents the mean results of two determinations performed  on different 
days. 
:~ (20 %  a.c.)  means that the highest stained cell count was 20 per cent above the control 
level. 
§ Potency for cytolysis of 60 4- 5 per cent of the cells; the remaining 40 per cent remained 
viable even at high concentrations of isoantiserum. 
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the  absorptive capacity of those  tissues.  No such  correlation was found for 
leukemias (see Discussion). 
Cytolysis of normal AKR  lymphocytes by C57BL/6 isoantisera: This system 
involves a  known difference in H-2 allele and presumably also differences in 
other  histoCompatibility factors  (17).  Isoantiserum  prepared  against  spleen 
gave strong cytolysis of spleen cells but very weak cytolysis of thymocytes; the 
isoantiserum against thymocytes also gave strong cytolysis of thymocytes but 
in contrast gave potent cytolysis of spleen cells (Table V). These are examples 
TABLE VI 
Absorption of CJHeB/Fe lsoantiserum against AKR Thymocytes by Viable Single 
Cell Suspensions of AKR Mice 
AKR tissue used for absorption  Absorptive capacity* relstive 
to AKR thymocytes 
Thymocytes .............................................. 
Neonatal thymocytes ...................................... 
Lymph node lymphocytes  .................................. 
Splenic lymphocytes  ....................................... 
Neonatal splenic lymphocytes .............................. 
Marrow cells  ............................................ 
Red blood cells  .......................................... 
per ~ 
100 
78 
5.7 
5.0 
<1.5 
<1.5 
<0.3 
L4946 leukemia  .......................................... 
$775 leukemia  ........................................... 
RA1 leukemia ........................................... 
RA3 leukemia  ........................................... 
RA4 leukemia  ........................................... 
RA5 leukemia  ........................................... 
13.3 
95 
4.4 
39 
7.4 
95 
* Calculated relative to absorption by the same number of AKR thymocytes. All results 
are the mean of two experiments. 
of cross-reactions.  Nevertheless,  the  relative potencies  of the  isoantisera  in- 
volved in these and other reactions (Table V) give evidence of wide quantitative 
differences in the surface antigens of thymocytes and of other normal lympho- 
cytes. 
C57BL/6 isoantisera failed to differentiate convincingly between lymph node 
and splenic lymphocytes (Table V). The lower potencies shown by isoantisera 
in their cytolysis of intraperitoneal lymphocytes may indicate a real difference 
in  susceptibility  to  isoantibodies.  Alternatively,  lymph  node  and  splenic 
lymphocytes may be more susceptible to immune cytolysis because their cell 
surfaces have been injured  during physical disruption  of the whole organs in 
preparation of single cell suspensions. 
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cytolysis by C57BL/6 isoantisera. The absorption datum (Table VI), the low 
potencies of isoantisera prepared against marrow cells (Tables IV and V), and 
the data obtained with heterologous antiserum (see above) suggest a different 
explanation. This is, that marrow cells possess a relatively low concentration of 
surface  isoantigens. 
Cytolysis  of AKR  leukemias  by  C3HeB/Fe  isoantisera:  In  contrast to the 
selective cytolysis of normal AKR tissues by C3HeB/Fe isoantisera (Table IV), 
TABLE VII 
Cytolysis of AKR Leukemia Cells by Isoantlsera Prepared in C3HeB/Fe Mice 
(Same H-2 Allde) against AKR Cells* 
Potency of C3HeB/Fe isoantisera for cytolysis of the following AKR leukemias: 
C.3HeB/Fe 
isoantisera against 
the following 
AKR cell types: 
Washed blood 
ceils 
Thymocytes 
Lymph nodes 
Spleen 
Marrow 
Liver 
L4946 leukemia 
BW5147 leu- 
kemia 
$775 leukemia 
T283 sarcoma 
IA946  BW5147 
long  long 
trans-  transplanted  planted 
<2  <2 
(39 % a.c,)  24 
<2  2.1 
(10 % a.c.)  28 
(23 % a.c.)  <2 
<2  <2 
(46 % a.c.)¶  30 
(19 % a.c.)  7.4¶ 
<2  <2 
<2  <2 
$775 
long 
trans- 
planted 
2.6 
103 
12.8~ 
122 
3.Mi 
<2 
127 
32~t 
4.7:~ 
2.3 
RA1 
5th 
gener- 
ation 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
RA2 
4th generation 
<2~ 
(20 % a.c.)~ 
n.t. 
174~, § 
<2~ 
6.7~ 
<2~ 
<2~t 
<2~ 
RA3 
1st generation 
(30 % a.c.) 
96§ 
2.5 
9711 
n.t, 
n.t. 
65 
a911 
4.7 
1.8 
RA3 
$th 
genera- 
tion 
1.8 
73 
n.t. 
58 
n.t. 
n.t. 
96 
n.t. 
n.t° 
n.t. 
* Each value represents the mean of two determinations, unless otherwise stated. 
~/Single determination. 
§ The stained cell count did not exceed 70 per cent at high isoantisemm concentrations. 
I1 The stained cell count did not exceed 80 per cent at high isoantiserum concentrations. 
¶ Strong prozone. 
four out of six AKR leukemias were highly sensitive to C3HeB/Fe isoantisera 
(Table VII). Isoantisera to thymocytes, spleen, and L4946 leukemia were the 
most potent. The relative potencies of C3HeB/Fe isoantisera were similar not 
only for cytolysis of three of the four highly sensitive leukemias, but also for 
cytolysis of normal thymocytes (Table VIII). This raises the possibility that the 
various C3HeB/Fe isoantisera all possessed antibodies directed against the same 
antigen (or group of antigens). Absorption studies (Table VI) support the sug- 
gestion that the same antigen was present in different concentration or spacial 
arrangement on the surface of normal thymocytes and of leukemias with high 
absorptive capacities. 424  AK.R THYMIC ANTIGEN 
Cytolysis of A KR leukemias by C57BL/6 isoantisera:  Cytolysis of normal AKR 
cells  by  C57BL/6  isoantisera  revealed  striking  differences  among  three  cell 
types:  first,  thymocytes;  secondly,  lymph node,  splenic,  and  intraperitoneal 
lymphocytes; and thirdly, marrow cells (Table V). Cytolysis of AKR leukemias 
by the same isoantisera  shows that certain  leukemias  reacted  almost exactly 
like one of these normal cell types (Table IX). 
For instance, IA946 leukemia (Table IX) reacted similarly to normal lymph 
TABLE VIII 
Rdati~e Potencies of C3HeB/Fe Isoantisera Prepared against AKR Cells  for Cytolysis of AKR 
Tkymocytes and of Three AKR Leukemias 
C3HeB/Fe  isoantisera against the 
following AKR cell types: 
Washed blood cells ............. 
Thymocytes  ................... 
Lymph nodes .................. 
Spleen ........................ 
Marrow ....................... 
Liver ......................... 
IA946 leukemia ................ 
BW5147 leukemia .............. 
$775 leukemia ................. 
T283 sarcoma .................. 
Relative potencies* of C3HeB/Fe  isoantisera for cytolysis of 
the following  AKR cell types: 
Thymocytes 
0.08 
1.0 
0.22 
1.2 
0.07 
0.02 
0.8 
0.6 
0.07 
0.03 
BW5147 
1.0 
0.09 
1.2 
1.2 
0.3 
$775 
0.03 
1.0 
0.12 
1.2 
0.03 
1.2 
0.3 
0.05 
0.02 
RA3 
1.0 
0.03 
1.0 
0.7 
0.2 
0.05 
0.02 
* Relative potency is expressed as the ratio of potencies of two isoantisera reacting with 
the same cell type. The potencies of all isoantisera have been compared with the potencies 
of the isoantiserum prepared against AKR thymocytes. Data taken from Tables IV and VII. 
node,  splenic,  or intraperitoneal  lymphocytes (Table V); the chief differences 
were somewhat stronger cytolysis of IA946 ceils by isoantisera against washed 
blood ceils and marrow. Absence of cytolytic potencies in excess of 2 for any 
C3HeB/Fe isoantiserum assayed against L4946 cells (Table VII) again indicates 
a strong similarity with non-thymic lymphocytes (Table IV). Further, when the 
absorptive capacity of IA946 cells for a  C3HeB/Fe isoantiserum  (Table VI) is 
calculated  on  the  basis  of unit  cell  surface  (19),  it  becomes 4.8  per  cent  or 
essentially  equal  to  that  of  splenic  lymphocytes.  1 The  above  data  strongly 
support the concept that IA946 leukemia is non-thymic in origin. 
Similar  considerations  indicate  that leukemia  RA1 is  non-thymic in  origin 
(Tables VI, VII, and IX). In contrast, leukemias BW5147, $775, RA2, and RA3 
1200 fresh AKR lymphocytes and L4946 cells had mean diameters of 6.1 and 10.3 #, which 
corresponded to mean spherical surface areas of 121 and 333 ~t  2, respectively. ARNOLD E.  RE1-F AND JOAN M.  V.  ALLEN  425 
reacted similarly to thymocytes with C3HeB/Fe isoantisera  (Tables IV, VII, 
and  VIH),  and  their  absorptive  capacities  for  such  isoantisera  were  high 
(Table VI). However, their cytolytic reactions with C57BL/6 isoantisera (Table 
IX) were more similar to those of splenic than of thymic lymphocytes (compare 
with Table V). The data suggest that these leukemias developed from the same 
stem cell as thymocytes, but possess higher concentrations of the antigens that 
correspond to the H-2  k and H-2  k' allele, than do thymocytes. 
TABLE IX 
C  ytolysis o] A K R Leukemia Cells by I soantiser  a Prepared in C57BL/6 Mice 
(Differ in H-2 Allele) against AKR Cells* 
C57BL/6 isoanti- 
sera against the 
following]AKR 
cell types: 
Washed blood 
cells 
Thymocytes 
Lymph nodes 
Spleen 
Marrow 
Liver 
IA946 leukemia 
BW5147 leu- 
kemia 
$775 leukemia 
T283 sarcoma 
Potency of C57BL/6  isoantisera for cytolysls  of the following  AKR leukemlas: 
L4946 
[ong trans- 
planted 
116 
24 
28 
218 
14 
4.3§ 
78 
31 
10.4 
1.S 
BWS147 
long 
transplanted 
30 
27 
3.o§ 
65 
(24 % a.c.) 
<2 
15.0 
10.8 
5.8 
<2 
$775 
long 
transplanted 
n.t. 
72 
(19 % a.c.) 
143 
s.8~ 
<2t 
27 
29 
13.4 
<2 
RAI 
$th gen- 
eration 
<2 
1.8 
<2 
19.4 
<2 
<2 
5.4 
4.8 
2.8 
<2 
RA2 
4th 
generation 
3oo~ 
86~ 
46~ 
626:~ 
21~ 
>1o~, II 
lO5~ 
I02, 
26~ 
lO.O, 
RA3 
Ist gen- 
eration 
8.9 
18.1 
<2 
74 
<2 
<2 
14.2 
8.8 
4.9 
<2 
RA3 
5th gen- 
eration 
n.t. 
n,t. 
n.t. 
58 
n.t. 
n.t. 
9.2 
10.6 
5.3 
<2 
* Each value represents  the mean of two determinations,  unless otherwise stated. 
Single determination. 
§ Strong prozone. 
][ Percentage of vitally stained cells did not exceed 53 per cent at high isoantiserum con- 
centrations.  Titer was not run out to low isoantiserum concentrations. 
Detailed data on immune cytolysis of leukemias RA4 and RA5 are not pre- 
sented here.  C3HeB/Fe  isoantisera  cytolyzed only RA5, while  C57BL[6  iso- 
antisera cytolyzed both leukemias.  Absorption experiments (Table VI) showed 
the same sharp quantitative distinction and the same correlation with cytolysis 
by C3HeB/Fe isoantisera that was found for the other leukemias. These data 
suggest that leukemias RA4 and RA5 are respectively non-thymic and thymic  in 
origin,  and  further  strengthen  the  close  correlation  between  the  results  of 
cytolysis and absorption experiments. 
Analysis of mixtures of normal and leukemic  lymphocytes: Various C3HeB/Fe 
isoantisera  caused strong cytolysis of thymus-derived leukemias  (Table  VII), 426  AKR THYMIC  ANTIGEN 
but had no effect on normal intraperitoneal lymphocytes (Table IV). Hence, 
C3HeB/Fe isoantisera could be used to determine the percentage of normal and 
thymus-derived leukemic cells in peritoneal exudates (Fig. 2, top). This method 
may prove to be a useful tool for study of the biology of recently derived AKR 
leukemias. 
TABLE X 
Absorptios of C3HeB/Fe Isoantiserum against AKR Thymocytes by Packed Residues Derived 
from Homogenates of AKR and RF Tissues 
Absorptive. _capacity* relative to  Mouse strain  Tissue residue used for absorption  AK.R thymus 
AKR 
AKR 
RF 
Thymus 
Brain 
Neonatal brain 
Appendix 
Lung 
Liver 
Skeletal muscle 
100 
107 
1.6 
3.3 
1.5 
0.9 
0.8 
Kidney 
Testis 
Hemisphere 
Pituitary 
Brain stem 
Cerebellum 
Spinal chord 
Olfactory bulb 
Sciatic nerve 
Thymus 
Brain 
Hemisphere 
Brain stem 
0.6 
0.6 
152 
89 
76 
57 
54 
41 
29 
71 
111 
181 
79 
* Calculated relative  to absorption by an AKR  thymic residue derived from the same 
wet weight of tissue.  All results  are the mean of two experiments. 
Antigenic stability of newly derived leukemia: Leukemia RA3 was subjected to 
immune cytolysis experiments both in its first and in its fifth transplant gener- 
ation.  Isoantisera  prepared  against  normal  tissues  showed  lower  cytolytic 
potencies for cells of the fifth transplant generation, while isoanfiserum against 
L4946  tumor showed higher potencies  (Tables VII,  and  IX).  However, the 
changes were too small to constitute definite evidence for a change in content 
of antigens between transplant generations 1 and 5. 
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and from spleen of the same AKR mouse, and the tumors that resulted were 
carried  separately. Ten  C57BL/6 isoantisera  of varying cytolytic potencies, 
when tested against cells of the fifth transplant generation of both tumor lines, 
gave  results  that  corresponded  closely. These  results  suggest  that  the  two 
leukemic tissues that were originally transplanted contained the same type of 
leukemic lymphocyte. 
Presence of the AKR thymic antigen in normal AKR tissues: The AKR thymic 
antigen was present in high concentration not only in thymus but also in all 
adult nervous tissues that were examined (Table X). Low levels of the antigen 
were present in adult lymph node lymphocytes, splenic lymphocytes, appendix 
and lung (Tables  VI and X). The antigen was almost fully developed in the 
thymus of newborn mice (Tables VI and XI); in contrast, neonatal brain con- 
talned less than 2 per cent of the antigen found in adult brain (Table X), and 
neonatal spleen contained less of the antigen than adult spleen (Table VI). 
Presence of AKR thymic antigen in other strains of mice: RF thymocytes were 
cytolyzed by C3HeB/Fe isoantiserum against AKR thymocytes at a potency 
similar  to that effective against the homologous cells (Table  XI). RF splenic 
lymphocytes, in common with AKR splenic lymphocytes, were not cytolyzed 
by this isoantiserum. The thymocytes of other strains that were tested gave no 
indication of cytolysis (Table XI). 
Absorption experiments  with thymocytes of various strains  were  equally 
clear-cut. Thymocytes  from RF mice absorbed almost as much of the C3HeB/Fe 
isoantiserum as  did AKR thymocytes. In  contrast,  thymocytes from other 
strains of mice did not absorb significant quantities of isoantibody (Table XII). 
The above results are consistent with the presence of the AKR thymic antigen 
on RF  thymocytes in a  quantity similar  to  that  on  the homologous  cells. 
Thymocytes from the other strains tested either lack this antigen, or possess 
less than one-hundredth of the amount present on the surface of AKR or RF 
thymocytes (Tables XI and XH). In tissues of RF mice that were tested, the 
distribution of the thymic antigen was similar to that in tissues of AKR mice 
(Table X). 
Distribution of C31~eB/Fe thymic antigen: Most experiments described above 
were done with C3HeB/Fe isoantisera  to AKR tissues. Experiments described 
below were done with the inverse isoantisera. In particular, AKR isoantisera to 
C3HeB/Fe thymocytes  and to C3HeB/Fe splenic lymphocytes  were used, since 
isoantisera to these tissues were most potent in the inverse situation (Table IV). 
The AKR isoantisera  cytolyzed thymocytes from all mouse  strains tested 
except  AKR and RF (Table  XI). The AKR isoantisera were inactive in cy- 
tolysis of splenic lymphocytes  from adult mice of strains C3HeB/Fe, A, C57BL, 
and  C57BL/6;  of  lymph  node  lymphocytes from  adult  mice  of  strains 
C3HeB/Fe, A, and C57BL/6; and of leukemia EL4 of C57BL mice.  These 
results parallel those obtained with the inverse isoantisera  (Table IV). TABLE  XI 
Cytolysis of  Thymocytes of  Various Mouse  Strains  by  Isoantisera  Prepared against AKR 
Thymocytes and against C3HeB/Fe Thymocytes* 
Thymocytes of mouse strain 
AKR 
AKR, neonatal 
RF 
C3HeB/Fe 
C3H/DiSn 
C3H/St* 
A 
A/He 
BALB/c 
C57BL 
C57BL, neonatal 
C57BL/6 
C57BL/10 
C57L 
C58 
DBA/1 
DBA  2 
ICR Swiss§ 
SWR 
129 
Cytolytic potencies shown against these thymocytes by 
•  isoantisera  prepared in: 
C3HeB/Fe mice vs. AKR 
thymocytes 
775 
710 
626 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
<2 
AKR mice vs. C3HeB/Fe 
thymocytes 
<2 
<2 
14.2 
15.9 
12.9 
12.3 
8.4 
13.9 
16.0 
11.0 
15.9 
14.1 
10.8 
5.1 
15.0 
13.2 
15.4 
13.8 
12.3 
* Mean results for either two or three experiments. 
;~ Subline of C3H/He. 
§ Non-inbred  strain  CDI  (Charles  River  Breeding  Laboratories,  Wilmington,  Massa- 
chusetts). 
TABLE  XlI 
Absorption of C3HeB/Fe Isoangserum against AKR Thymocytes by Viable 
Thymocytes from Various Strains of Mice 
Source of thymocytes  Absorptive capacity relative to AKR thymocytes 
AKR 
RF 
C3HeB/Fe 
A 
BALB/c 
C57BL/6 
C57BL/10 
DBA/1 
DBA/2 
SWR 
jger cent 
100 
87 
<2.0 
<2.0 
<2.0 
<2.0 
<2.0 
<2.0 
<2.0 
<2.0 
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Data obtained by absorption of an AKR isoantiserum with different numbers 
of intact C3HeB/Fe thymocytes gave a straight line parallel to that in Fig. 3. 
This line was used as caliberation  curve for the quantitative determination of 
the absorptive capacities of intact cells or tissue residues. 
An AKR isoantiserum to C3HeB/Fe splenic lymphocytes was absorbed with 
intact cells from strains that possessed the C3HeB/Fe thymic antigen. Relative 
to absorption by adult C3HeB/Fe thymocytes, the absorptive  capacities  of 
these cells were as follows: thymocytes from C57BL/6, C57BL, and neonatal 
CSTBL mice, 88,  74, and 74 per cent respectively;  lymph node lymphocytes 
from C3HeB/Fe, C57BL/6, and C57BL mice, 19,  11, and 16 per cent respec- 
tively; splenic lymphocytes  from the same three strains, 12, 5.3, and 9.8 per cent 
respectively; neonatal splenic lymphocytes of C57BL and ICR Swiss mice, 2.7 
and 2.3 per cent respectively;  and EL4 leukemia of C57BL mice, 11.4 per cent, 
or 1.7 per cent if calculated on the basis of equal cell surface area rather than 
equal cell number.  2 These results are similar to those obtained with an inverse 
isoantiserum (Table VI). 
The same AKR isoantiserum was absorbed with tissue residues from strains 
C3HeB/Fe and CS7BL/6. Since results for the two strains were closely similar, 
they have been averaged: the absorptive capacity of thymus, brain, appendix, 
lung, liver, and kidney  was 100, 122, 3.0, 1.3, 0.65, and 0.49 per cent respectively. 
Neonatal brain of C57BL, ICR Swiss, and A mice averaged 2.4 per cent of the 
absorptive capacity possessed by adult brain  of these three strains.  Again, 
these data resemble those obtained with an inverse isoantiserum  (Table X). 
DISCUSSION 
Gorer  and coworkers reported three X  antigens present specifically in EL 
leukemias  of C57BL mice: EIA X, EL6 X, and EL8 X. Since some EL leu- 
kemias arose in thymus, they searched for X antigens in that tissue, but were not 
successful. EL leukemias  could  not be  cytolyzed by isoantibodies  to the X 
antigens (2). 
In contrast, isoantibodies  to the AKR or C3HeB/Fe thymic antigens cy- 
tolyzed thymocytes that possessed either of these antigens (Table XI). Further, 
EIA leukemia did not absorb measurable quantities of an isoantiserum to AKR 
thymus, and absorbed less isoantiserum to C3HeB/Fe thymus than did normal 
splenic lymphocytes of strain C57BL. These data indicate that both the present 
thyrnic antigens are distinct from EL4 X and cast doubt on identity with EL6 X 
or EL8 X. 
Old, Boyse, and Stockert reported presence of the LT antigen in some C57BL 
leukemias (4), reminiscent  of Gorer's  results (2, 20). However, the LT antigen 
was distinct from EL4 X. Their findings include absence of the LT antigen in 
s The mean diameter of EL4 cells was 15.6 ~. 430  AK_-~ THYMIC  ANTIGEN 
normal C57BL thymus, and presence of the LT antigen in A and C58 thymus 
(4). 
These latter data clearly distinguish the LT antigen both from the AKR and 
from the C3HeB/Fe thymic antigen (Table XI). More recent work (21, 22) has 
confirmed the differentiation between the LT and AKR antigens.  Since the LT 
antigen is present in A but not in C57BL thymus (4),  while  the C3HeB/Fe 
thymic antigen is present in both strains (Table XI), it appears that more than 
one thymic antigen can be present in thymus of a single inbred mouse strain. 
The AKR and  C3HeB/Fe thymic antigens  could represent previously un- 
recognized  expressions  of known mouse histocompatibility (H) factors. Com- 
parison  of the present Table XI with Table  10 of Amos et  al.  (17) excludes 
association of either antigen with any of the six known mouse histocompati- 
bility factors  H-1  to  H-6.  Moreover,  since  thyrnocytes  of female  AKR  or 
C3HeB/Fe mice possess a full complement of the respective thymic antigens, 
Y-linked histocompatibility antigens (23) are not implicated. 
Amos  et  al.  have  suggested that  apparently  new serologically  determined 
mouse antigens be first designated by Greek letters (17). In line with this sug- 
gestion,  the names 0-AKR and 0-C3HeB/Fe are proposed for the two thymic 
antigens described here and (in the case of the AKR antigen) previously (9). 
When  the precise relationship  of these antigens  to  the new mouse antigens 
presently under investigation by Snell (24) and others (21) has been determined, 
perhaps a different nomenclature will be more appropriate. 
The disproportionately high antibody response to viable IA946 cells (Table 
IV), relative to the absorption of isoantibody by these ceils (Table VI), requires 
explanation.  At low doses of antigen,  antibody response is loosely correlated 
with the quantity of antigen injected (25). More important, the initial multipli- 
cation of viable tumor cells in an incompatible host provides a powerful stimulus 
to antibody response (24, 26-28). 
Lymphocytes resist immune cytolysis, unless a  minimum  concentration  of 
sites that can bind the relevant antibodies is present on their surfaces (14, 19, 
29, 30).  If this minimum is exceeded and the potencies of the isoantisera are 
sufficiently  high  to avoid prozone formation,  then immune cytolysis provides 
clear-cut,  quantitative  evidence  of  an  immune  reaction.  However,  present 
results support the conclusion  of M611er (30), that absorption experiments are 
more sensitive. 
The LT antigen  is  present  in  certain  C57BL leukemias but absent from 
thymus and other normal C57BL tissues (4); one possible explanation is that 
the LT antigen is latent in this strain. Therefore, the high content of the 8-AKR 
antigen in certain AKR leukemias (Table VI) does not necessarily prove that 
these leukemias originated in thymus; they may have originated in a cellular 
precursor of thymocytes. This latter possibility is supported by the difference 
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and with leukemias that possessed a high content of 0-AKR, such as $775 and 
RA3  (Tables  V and IX). In contrast, the cytolytic reactions  with C57BL/6 
isoantisera strengthen the evidence  that leukemias  with low contents of the 
0-AKR antigen were of non-thymic origin. 
The 0-AKR and the 0-C3HeB/Fe antigens had an inverse  distribution in 
eighteen mouse strains (Table XI). Both antigens had a similar distribution 
in tissues of the strains that were tested. There were no exceptions to these two 
rules. 
It was unexpected to find the same antigen (either 0-AKR or 0-C3HeB/Fe) 
present in high amounts in thymus and in nervous  tissue  of each of the six 
strains tested. However,  neonatal brain possessed only between  1.5  and 2.8 
per cent of the content of antigen found in adult brain in the four strains studied. 
In contrast, the antigen was almost fully developed in neonatal thymus. 
The above results suggest that 0-AKR and 0-C3HeB/Fe antigens originated 
either in the thymus or in closely related cellular precursors. The concept that 
an immunological  maturation of mouse brain takes place  after birth is new. 
Present indications of a close immunological relation among thymus, leukemias, 
and nervous tissues require further investigation. 
The low but definite content of the 0-AKR or 0-C3HeB/Fe antigen in spleen, 
lymph nodes,  appendix,  and lung of the strains studied may have been due 
either to presence  of the respective  antigens on cells of these tissues  or  to 
migration of thymocytes into the tissues. It remains to be determined whether 
the development of 0-isoantigens in neonatal spleen parallels the development of 
H-2 isoantigens,  which has been well documented by the M611ers (14, 16,  19, 
30). The present data fit the concept  that thymocytes migrate to neonatal 
spleen and there induce differentiation of lymphoblasts to immune competent 
cells (31-35). 
SUMMARY 
A clear-cut  serological differentiation between AKR lymphocytes of thymic 
and non-thymic  origin is reported: these two cell types are antigenically  distinct. 
In newborn mice, the AKR thymic antigen was found at a high concentration 
only in thymus. In adult mice, the antigen was present at a high level in thymus, 
all nervous tissues tested, and some leukemias. It was present at much lower 
levels in lymph node lymphocytes, splenic lymphocytes, appendix,  lung,  and 
certain other leukemias, which appeared to be of non-thymic origin. The AKR 
thymic antigen was present at a high level in thymus and nervous tissues of RF 
mice, but was absent from thymocytes of sixteen other mouse strains. 
These sixteen strains possessed the C3HeB/Fe thymic antigen. The distribu- 
tion of this antigen in neonatal and adult tissues  of the strains tested was 
s~m~lar to that of the AKR thymlc antigen in AKR mice. No exceptions were 
found. 432  AKR  T~IC  ANTIGEN 
These results were obtained by use of immune cytolysis, and of a new method 
for the quantitative  treatment of data from absorption experiments. 
Best thanks are due to Flaviu C. A. Romanul for help with dissection of nervous tissues, 
and to Theodore  S. Hauschka and Charles A. Apffel for gifts of mice and tumors. 
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